Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1995 Aug;69(8):4854–4862. doi: 10.1128/jvi.69.8.4854-4862.1995

The peri-kappa B site mediates human immunodeficiency virus type 2 enhancer activation in monocytes but not in T cells.

N M Clark 1, M C Hannibal 1, D M Markovitz 1
PMCID: PMC189299  PMID: 7609053

Abstract

Human immunodeficiency virus type 2 (HIV-2), like HIV-1, causes AIDS and is associated with AIDS cases primarily in West Africa. HIV-1 and HIV-2 display significant differences in nucleic acid sequence and in the natural history of clinical disease. Consistent with these differences, we have previously demonstrated that the enhancer/promoter region of HIV-2 functions quite differently from that of HIV-1. Whereas activation of the HIV-1 enhancer following T-cell stimulation is mediated largely through binding of the transcription factor NF-kappa B to two adjacent kappa B sites in the HIV-1 long terminal repeat, activation of the HIV-2 enhancer in monocytes and T cells is dependent on four cis-acting elements: a single kappa B site, two purine-rich binding sites, PuB1 and PuB2, and a pets site. We have now identified a novel cis-acting element within the HIV-2 enhancer, immediately upstream of the kappa B site, designated peri-kappa B. This site is conserved among isolates of HIV-2 and the closely related simian immunodeficiency virus, and transfection assays show this site to mediate HIV-2 enhancer activation following stimulation of monocytic but not T-cell lines. This is the first description of an HIV-2 enhancer element which displays such monocyte specificity, and no comparable enhancer element has been clearly defined for HIV-1. While a nuclear factor(s) from both peripheral blood monocytes and T cells binds the peri-kappa B site, electrophoretic mobility shift assays suggest that either a different protein binds to this site in monocytes versus T cells or that the protein recognizing this enhancer element undergoes differential modification in monocytes and T cells, thus supporting the transfection data. Further, while specific constitutive binding to the peri-kappa B site is seen in monocytes, stimulation with phorbol esters induces additional, specific binding. Understanding the monocyte-specific function of the peri-kappa B factor may ultimately provide insight into the different role monocytes and T cells play in HIV pathogenesis.

Full Text

The Full Text of this article is available as a PDF (639.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert J., Bredberg U., Chiodi F., Böttiger B., Fenyö E. M., Norrby E., Biberfeld G. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. AIDS Res Hum Retroviruses. 1987 Spring;3(1):3–10. doi: 10.1089/aid.1987.3.3. [DOI] [PubMed] [Google Scholar]
  2. Ancelle R., Bletry O., Baglin A. C., Brun-Vezinet F., Rey M. A., Godeau P. Long incubation period for HIV-2 infection. Lancet. 1987 Mar 21;1(8534):688–689. doi: 10.1016/s0140-6736(87)90454-5. [DOI] [PubMed] [Google Scholar]
  3. Arya S. K., Mohr J. R. Conditional regulatory elements of human immunodeficiency virus type 2 long terminal repeat. J Gen Virol. 1994 Sep;75(Pt 9):2253–2260. doi: 10.1099/0022-1317-75-9-2253. [DOI] [PubMed] [Google Scholar]
  4. Bednarik D. P., Folks T. M. Mechanisms of HIV-1 latency. AIDS. 1992 Jan;6(1):3–16. doi: 10.1097/00002030-199201000-00001. [DOI] [PubMed] [Google Scholar]
  5. Carlsson P., Waterman M. L., Jones K. A. The hLEF/TCF-1 alpha HMG protein contains a context-dependent transcriptional activation domain that induces the TCR alpha enhancer in T cells. Genes Dev. 1993 Dec;7(12A):2418–2430. doi: 10.1101/gad.7.12a.2418. [DOI] [PubMed] [Google Scholar]
  6. Chakrabarti L., Guyader M., Alizon M., Daniel M. D., Desrosiers R. C., Tiollais P., Sonigo P. Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature. 1987 Aug 6;328(6130):543–547. doi: 10.1038/328543a0. [DOI] [PubMed] [Google Scholar]
  7. Clark N. M., Smith M. J., Hilfinger J. M., Markovitz D. M. Activation of the human T-cell leukemia virus type I enhancer is mediated by binding sites for Elf-1 and the pets factor. J Virol. 1993 Sep;67(9):5522–5528. doi: 10.1128/jvi.67.9.5522-5528.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clavel F., Guyader M., Guétard D., Sallé M., Montagnier L., Alizon M. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature. 1986 Dec 18;324(6098):691–695. doi: 10.1038/324691a0. [DOI] [PubMed] [Google Scholar]
  9. Clavel F., Guétard D., Brun-Vézinet F., Chamaret S., Rey M. A., Santos-Ferreira M. O., Laurent A. G., Dauguet C., Katlama C., Rouzioux C. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986 Jul 18;233(4761):343–346. doi: 10.1126/science.2425430. [DOI] [PubMed] [Google Scholar]
  10. Clavel F., Mansinho K., Chamaret S., Guetard D., Favier V., Nina J., Santos-Ferreira M. O., Champalimaud J. L., Montagnier L. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med. 1987 May 7;316(19):1180–1185. doi: 10.1056/NEJM198705073161903. [DOI] [PubMed] [Google Scholar]
  11. Cortes E., Detels R., Aboulafia D., Li X. L., Moudgil T., Alam M., Bonecker C., Gonzaga A., Oyafuso L., Tondo M. HIV-1, HIV-2, and HTLV-I infection in high-risk groups in Brazil. N Engl J Med. 1989 Apr 13;320(15):953–958. doi: 10.1056/NEJM198904133201501. [DOI] [PubMed] [Google Scholar]
  12. De Cock K. M., Adjorlolo G., Ekpini E., Sibailly T., Kouadio J., Maran M., Brattegaard K., Vetter K. M., Doorly R., Gayle H. D. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA. 1993 Nov 3;270(17):2083–2086. doi: 10.1001/jama.270.17.2083. [DOI] [PubMed] [Google Scholar]
  13. Dignam J. D., Lebovitz R. M., Roeder R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983 Mar 11;11(5):1475–1489. doi: 10.1093/nar/11.5.1475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dynan W. S., Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell. 1983 Nov;35(1):79–87. doi: 10.1016/0092-8674(83)90210-6. [DOI] [PubMed] [Google Scholar]
  15. Embretson J., Zupancic M., Ribas J. L., Burke A., Racz P., Tenner-Racz K., Haase A. T. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993 Mar 25;362(6418):359–362. doi: 10.1038/362359a0. [DOI] [PubMed] [Google Scholar]
  16. Emerman M., Guyader M., Montagnier L., Baltimore D., Muesing M. A. The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. EMBO J. 1987 Dec 1;6(12):3755–3760. doi: 10.1002/j.1460-2075.1987.tb02710.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fauci A. S., Schnittman S. M., Poli G., Koenig S., Pantaleo G. NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991 Apr 15;114(8):678–693. doi: 10.7326/0003-4819-114-8-678. [DOI] [PubMed] [Google Scholar]
  18. Fletcher C., Heintz N., Roeder R. G. Purification and characterization of OTF-1, a transcription factor regulating cell cycle expression of a human histone H2b gene. Cell. 1987 Dec 4;51(5):773–781. doi: 10.1016/0092-8674(87)90100-0. [DOI] [PubMed] [Google Scholar]
  19. Folks T. M., Justement J., Kinter A., Dinarello C. A., Fauci A. S. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science. 1987 Nov 6;238(4828):800–802. doi: 10.1126/science.3313729. [DOI] [PubMed] [Google Scholar]
  20. Galas D. J., Schmitz A. DNAse footprinting: a simple method for the detection of protein-DNA binding specificity. Nucleic Acids Res. 1978 Sep;5(9):3157–3170. doi: 10.1093/nar/5.9.3157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gao F., Yue L., White A. T., Pappas P. G., Barchue J., Hanson A. P., Greene B. M., Sharp P. M., Shaw G. M., Hahn B. H. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature. 1992 Aug 6;358(6386):495–499. doi: 10.1038/358495a0. [DOI] [PubMed] [Google Scholar]
  22. Gartner S., Markovits P., Markovitz D. M., Betts R. F., Popovic M. Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA. 1986 Nov 7;256(17):2365–2371. [PubMed] [Google Scholar]
  23. Gartner S., Markovits P., Markovitz D. M., Kaplan M. H., Gallo R. C., Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986 Jul 11;233(4760):215–219. doi: 10.1126/science.3014648. [DOI] [PubMed] [Google Scholar]
  24. Gendelman H. E., Orenstein J. M., Martin M. A., Ferrua C., Mitra R., Phipps T., Wahl L. A., Lane H. C., Fauci A. S., Burke D. S. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med. 1988 Apr 1;167(4):1428–1441. doi: 10.1084/jem.167.4.1428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ghosh D. A relational database of transcription factors. Nucleic Acids Res. 1990 Apr 11;18(7):1749–1756. doi: 10.1093/nar/18.7.1749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Gmelig-Meyling F., Waldmann T. A. Separation of human blood monocytes and lymphocytes on a continuous Percoll gradient. J Immunol Methods. 1980;33(1):1–9. doi: 10.1016/0022-1759(80)90077-0. [DOI] [PubMed] [Google Scholar]
  27. Gorman C. M., Moffat L. F., Howard B. H. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 1982 Sep;2(9):1044–1051. doi: 10.1128/mcb.2.9.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Gutierrez C., Bernabe R. R., Vega J., Kreisler M. Purification of human T and B cells by a discontinuous density gradient of percoll. J Immunol Methods. 1979;29(1):57–63. doi: 10.1016/0022-1759(79)90125-x. [DOI] [PubMed] [Google Scholar]
  29. Guyader M., Emerman M., Sonigo P., Clavel F., Montagnier L., Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987 Apr 16;326(6114):662–669. doi: 10.1038/326662a0. [DOI] [PubMed] [Google Scholar]
  30. Hannibal M. C., Markovitz D. M., Clark N., Nabel G. J. Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals. J Virol. 1993 Aug;67(8):5035–5040. doi: 10.1128/jvi.67.8.5035-5040.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hannibal M. C., Markovitz D. M., Nabel G. J. Multiple cis-acting elements in the human immunodeficiency virus type 2 enhancer mediate the response to T-cell receptor stimulation by antigen in a T-cell hybridoma line. Blood. 1994 Apr 1;83(7):1839–1846. [PubMed] [Google Scholar]
  32. Hilfinger J. M., Clark N., Smith M., Robinson K., Markovitz D. M. Differential regulation of the human immunodeficiency virus type 2 enhancer in monocytes at various stages of differentiation. J Virol. 1993 Jul;67(7):4448–4453. doi: 10.1128/jvi.67.7.4448-4453.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ho D. D., Moudgil T., Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989 Dec 14;321(24):1621–1625. doi: 10.1056/NEJM198912143212401. [DOI] [PubMed] [Google Scholar]
  34. Kanki P. J. Biologic features of HIV-2. An update. AIDS Clin Rev. 1991:17–38. [PubMed] [Google Scholar]
  35. Kanki P. J. Clinical significance of HIV-2 infection in West Africa. AIDS Clin Rev. 1989:95–108. [PubMed] [Google Scholar]
  36. Kemler I., Schaffner W. Octamer transcription factors and the cell type-specificity of immunoglobulin gene expression. FASEB J. 1990 Mar;4(5):1444–1449. doi: 10.1096/fasebj.4.5.2407588. [DOI] [PubMed] [Google Scholar]
  37. Kinter A. L., Poli G., Maury W., Folks T. M., Fauci A. S. Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J Virol. 1990 Sep;64(9):4306–4312. doi: 10.1128/jvi.64.9.4306-4312.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. LaBella F., Sive H. L., Roeder R. G., Heintz N. Cell-cycle regulation of a human histone H2b gene is mediated by the H2b subtype-specific consensus element. Genes Dev. 1988 Jan;2(1):32–39. doi: 10.1101/gad.2.1.32. [DOI] [PubMed] [Google Scholar]
  39. Leiden J. M., Wang C. Y., Petryniak B., Markovitz D. M., Nabel G. J., Thompson C. B. A novel Ets-related transcription factor, Elf-1, binds to human immunodeficiency virus type 2 regulatory elements that are required for inducible trans activation in T cells. J Virol. 1992 Oct;66(10):5890–5897. doi: 10.1128/jvi.66.10.5890-5897.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Levy J. A. The multifaceted retrovirus. Cancer Res. 1986 Nov;46(11):5457–5468. [PubMed] [Google Scholar]
  41. Lu Y. C., Touzjian N., Stenzel M., Dorfman T., Sodroski J. G., Haseltine W. A. Identification of cis-acting repressive sequences within the negative regulatory element of human immunodeficiency virus type 1. J Virol. 1990 Oct;64(10):5226–5229. doi: 10.1128/jvi.64.10.5226-5229.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Lu Y., Stenzel M., Sodroski J. G., Haseltine W. A. Effects of long terminal repeat mutations on human immunodeficiency virus type 1 replication. J Virol. 1989 Sep;63(9):4115–4119. doi: 10.1128/jvi.63.9.4115-4119.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Luo Y., Fujii H., Gerster T., Roeder R. G. A novel B cell-derived coactivator potentiates the activation of immunoglobulin promoters by octamer-binding transcription factors. Cell. 1992 Oct 16;71(2):231–241. doi: 10.1016/0092-8674(92)90352-d. [DOI] [PubMed] [Google Scholar]
  44. Markovitz D. M., Hannibal M. C., Smith M. J., Cossman R., Nabel G. J. Activation of the human immunodeficiency virus type 1 enhancer is not dependent on NFAT-1. J Virol. 1992 Jun;66(6):3961–3965. doi: 10.1128/jvi.66.6.3961-3965.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Markovitz D. M., Hannibal M., Perez V. L., Gauntt C., Folks T. M., Nabel G. J. Differential regulation of human immunodeficiency viruses (HIVs): a specific regulatory element in HIV-2 responds to stimulation of the T-cell antigen receptor. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9098–9102. doi: 10.1073/pnas.87.23.9098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Markovitz D. M. Infection with the human immunodeficiency virus type 2. Ann Intern Med. 1993 Feb 1;118(3):211–218. doi: 10.7326/0003-4819-118-3-199302010-00010. [DOI] [PubMed] [Google Scholar]
  47. Markovitz D. M., Smith M. J., Hilfinger J., Hannibal M. C., Petryniak B., Nabel G. J. Activation of the human immunodeficiency virus type 2 enhancer is dependent on purine box and kappa B regulatory elements. J Virol. 1992 Sep;66(9):5479–5484. doi: 10.1128/jvi.66.9.5479-5484.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Marlink R., Kanki P., Thior I., Travers K., Eisen G., Siby T., Traore I., Hsieh C. C., Dia M. C., Gueye E. H. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994 Sep 9;265(5178):1587–1590. doi: 10.1126/science.7915856. [DOI] [PubMed] [Google Scholar]
  49. Moses A. V., Ibanez C., Gaynor R., Ghazal P., Nelson J. A. Differential role of long terminal repeat control elements for the regulation of basal and Tat-mediated transcription of the human immunodeficiency virus in stimulated and unstimulated primary human macrophages. J Virol. 1994 Jan;68(1):298–307. doi: 10.1128/jvi.68.1.298-307.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Murre C., Voronova A., Baltimore D. B-cell- and myocyte-specific E2-box-binding factors contain E12/E47-like subunits. Mol Cell Biol. 1991 Feb;11(2):1156–1160. doi: 10.1128/mcb.11.2.1156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Nabel G., Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 1987 Apr 16;326(6114):711–713. doi: 10.1038/326711a0. [DOI] [PubMed] [Google Scholar]
  52. Nakanishi Y., Masamune Y., Kobayashi N. A novel cis-acting element that controls transcription of human immunodeficiency virus type 1 DNA, depending on cell type. J Virol. 1991 Nov;65(11):6334–6338. doi: 10.1128/jvi.65.11.6334-6338.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Orenstein J. M., Meltzer M. S., Phipps T., Gendelman H. E. Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J Virol. 1988 Aug;62(8):2578–2586. doi: 10.1128/jvi.62.8.2578-2586.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Pantaleo G., Graziosi C., Demarest J. F., Butini L., Montroni M., Fox C. H., Orenstein J. M., Kotler D. P., Fauci A. S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993 Mar 25;362(6418):355–358. doi: 10.1038/362355a0. [DOI] [PubMed] [Google Scholar]
  55. Pierani A., Heguy A., Fujii H., Roeder R. G. Activation of octamer-containing promoters by either octamer-binding transcription factor 1 (OTF-1) or OTF-2 and requirement of an additional B-cell-specific component for optimal transcription of immunoglobulin promoters. Mol Cell Biol. 1990 Dec;10(12):6204–6215. doi: 10.1128/mcb.10.12.6204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Poli G., Bressler P., Kinter A., Duh E., Timmer W. C., Rabson A., Justement J. S., Stanley S., Fauci A. S. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med. 1990 Jul 1;172(1):151–158. doi: 10.1084/jem.172.1.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Queen C., Baltimore D. Immunoglobulin gene transcription is activated by downstream sequence elements. Cell. 1983 Jul;33(3):741–748. doi: 10.1016/0092-8674(83)90016-8. [DOI] [PubMed] [Google Scholar]
  58. Ruef C., Dickey P., Schable C. A., Griffith B., Williams A. E., D'Aquila R. T. A second case of the acquired immunodeficiency syndrome due to human immunodeficiency virus type 2 in the United States: the clinical implications. Am J Med. 1989 Jun;86(6 Pt 1):709–712. doi: 10.1016/0002-9343(89)90451-8. [DOI] [PubMed] [Google Scholar]
  59. Saksela K., Stevens C., Rubinstein P., Baltimore D. Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1104–1108. doi: 10.1073/pnas.91.3.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Schrier R. D., McCutchan J. A., Venable J. C., Nelson J. A., Wiley C. A. T-cell-induced expression of human immunodeficiency virus in macrophages. J Virol. 1990 Jul;64(7):3280–3288. doi: 10.1128/jvi.64.7.3280-3288.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Singh H., Sen R., Baltimore D., Sharp P. A. A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature. 1986 Jan 9;319(6049):154–158. doi: 10.1038/319154a0. [DOI] [PubMed] [Google Scholar]
  62. Thompson C. B., Wang C. Y., Ho I. C., Bohjanen P. R., Petryniak B., June C. H., Miesfeldt S., Zhang L., Nabel G. J., Karpinski B. cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1. Mol Cell Biol. 1992 Mar;12(3):1043–1053. doi: 10.1128/mcb.12.3.1043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Tong-Starksen S. E., Welsh T. M., Peterlin B. M. Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals. J Immunol. 1990 Dec 15;145(12):4348–4354. [PubMed] [Google Scholar]
  64. Wang C. Y., Petryniak B., Ho I. C., Thompson C. B., Leiden J. M. Evolutionarily conserved Ets family members display distinct DNA binding specificities. J Exp Med. 1992 May 1;175(5):1391–1399. doi: 10.1084/jem.175.5.1391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Waterman M. L., Jones K. A. Purification of TCF-1 alpha, a T-cell-specific transcription factor that activates the T-cell receptor C alpha gene enhancer in a context-dependent manner. New Biol. 1990 Jul;2(7):621–636. [PubMed] [Google Scholar]
  66. Wiley C. A., Schrier R. D., Nelson J. A., Lampert P. W., Oldstone M. B. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7089–7093. doi: 10.1073/pnas.83.18.7089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Xiao J. H., Davidson I., Ferrandon D., Rosales R., Vigneron M., Macchi M., Ruffenach F., Chambon P. One cell-specific and three ubiquitous nuclear proteins bind in vitro to overlapping motifs in the domain B1 of the SV40 enhancer. EMBO J. 1987 Oct;6(10):3005–3013. doi: 10.1002/j.1460-2075.1987.tb02606.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Zeichner S. L., Kim J. Y., Alwine J. C. Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat. J Virol. 1991 May;65(5):2436–2444. doi: 10.1128/jvi.65.5.2436-2444.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES